Advanced Intrahepatic Cholangiocarcinoma Clinical Trial
Official title:
A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined With Sintilimab Plus Lenvatinib as First-line Treatment in Patients With Unresectable Advanced Intrahepatic Cholangiocarcinoma (ICC)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib as first-line treatment in patients with advanced ICC.
Recent studies have suggested that local destruction of tumor tissue by cryoablation induced activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens. While pd-1 blocking antibody interferes with PD-1 mediated T-cell regulatory signaling. And combination of pd-1 blocking antibody plus lenvatinib showed increased ORR in many types of human cancers. Therefore, the objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib as first-line treatment in patients with advanced ICC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04353375 -
Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT01039181 -
Calcitriol in Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 |